Deka Biosciences, Inc

United States - Germantown, MD

• 16/11/2021
• Series A
• $20,000,000

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Related People

John MummCo Founder

United States - Bethesda, Maryland

20 plus years experience in academia and biotechnology/pharmaceutical industry in positions of increasing responsibility.

Primary focus has been in discovery research at the interface between cancer biology and the adaptive immune response.

Significant experience in discovery biology, i.e. what do tumors secrete that negatively impact the immune response, and how to therapeutically overcome these barriers.

Previously accumulated significant experience in translational research attempting to render cytokines into therapeutic entities.

Recent experience has been directed toward manufacturing biologics for Phase 1 and 2 immunoncology clinical trials.

Specialties: Discovery Research, Biologics Manufacturing
Oncology:Immune Interface,
Cytokine Biology
Translational Research

LinkedIn https://www.linkedin.com/in/john-mumm-4442071/